Aktis Oncology initiated with an Overweight at JPMorgan

JPMorgan initiated coverage of Aktis Oncology (AKTS) with an Overweight rating and $30 price target The company has an “attractive” platform for developing radiopharmaceutical therapies, a novel means of delivering targeted radiation for cancer, the analyst tells investors in a research note. The firm sees radiopharmaceutical therapy modality “taking off” in the coming years and thinks Aktis is “entering at a sweet spot” where it can develop “first-in-class products in a relatively open field.”